$295.00
GLP-3 Microdosed (Retatrutide) is a synthetic tri-agonist peptide designed for research involving metabolic and endocrine signaling pathways. It interacts with glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, enabling investigation of multi-receptor activation in experimental models. By engaging these receptor systems, Retatrutide is studied for its role in coordinated metabolic regulation, energy balance signaling, and receptor-mediated intracellular pathway dynamics. Preclinical research utilizes Retatrutide to examine receptor crosstalk, glucose metabolism mechanisms, lipid utilization pathways, and integrated endocrine network responses under controlled laboratory conditions.
For research use only. Not for human consumption.
References:
Coskun T et al., Cell Metabolism, 2022
Jastreboff AM et al., New England Journal of Medicine, 2023
Müller TD et al., Nature Reviews Drug Discovery, 2022
GLP-3 Microdosed (Retatrutide) is a synthetic multi-receptor agonist peptide developed for laboratory research involving metabolic and endocrine signaling systems. It is designed to interact with GLP-1, GIP, and glucagon receptors and is studied in experimental models examining coordinated receptor activation and metabolic regulation.
Biochemical Characteristics
Retatrutide is a large synthetic peptide engineered to activate three distinct receptor pathways. Its molecular structure enables receptor binding across GLP-1, GIP, and glucagon systems, supporting investigation of integrated metabolic signaling. The peptide demonstrates receptor affinity suitable for controlled in vitro and preclinical experimental applications.
Research Applications
Retatrutide is commonly utilized in laboratory studies exploring metabolic regulation, receptor signaling kinetics, peptide stability, and multi-receptor interaction dynamics. It is applied in experimental models evaluating glucose regulation mechanisms, lipid metabolism pathways, and endocrine network coordination.
Pathway / Mechanistic Context
Mechanistic research involving Retatrutide focuses on simultaneous activation of GLP-1, GIP, and glucagon receptor pathways. Studies examine downstream intracellular signaling cascades, receptor crosstalk, metabolic pathway modulation, and feedback regulation under controlled experimental conditions.
Preclinical Research Summary
Preclinical investigations have evaluated Retatrutide in in vitro and experimental models to assess its multi-receptor activity and effects on metabolic signaling systems. These studies support its continued use as a research tool for analyzing integrated endocrine and metabolic responses.
Form & Analytical Testing
GLP-3 Microdosed (Retatrutide) is supplied as a lyophilized peptide and undergoes analytical verification, including HPLC testing, to confirm identity, purity, and consistency. Analytical validation ensures suitability for laboratory research applications requiring precise peptide characterization.
RUO Disclaimer
This product is intended strictly for research and laboratory use only. It is not approved for human consumption, medical treatment, veterinary use, cosmetic application, or diagnostic purposes. Handling should be performed only by qualified professionals trained in proper laboratory procedures.
Reviews
There are no reviews yet.